Tune Into Rocket Doctor AI’s Town Hall June 3
Rocket Doctor AI’s latest quarter results read like a company that is still early in its expansion across the United States, but now has enough data points to start testing the long‑term thesis in a more grounded way.
On the top line, revenue for Q1 2026 came in at about $737,000, up 5.7% from Q4 2025 and almost 40% from Q3 2025. That may not sound dramatic in absolute dollars, but it’s worth remembering that meaningful revenue only really began after the acquisition of Rocket Doctor Inc. in 2025. What matters here is the pattern: three consecutive quarters of sequential growth and a business that is scaling rather than stalling as integration progresses.
The most interesting part of this update sits in the operating metrics and the U.S. expansion story. Canada remains an equally vital market for Rocket Doctor, and Q1 2026 completed patient visit increased by approximately 25% (to about 48,000) compared to Q1 2025. But management highlights that U.S. completed patient visits jumped 283% quarter‑over‑quarter, from 177 in Q4 2025 to 678 in Q1 2026. That momentum carried into April, with over 500 visits that month alone (69% monthly increase), and May is expected to show further growth. To support this, Rocket Doctor has doubled the number of physicians credentialed on its U.S. platform to 80 as of the end of May, and plans to increase that pace to handle the growing patient load.
There are a few technical and accounting details worth noting as well. For its U.S. operations, Rocket Doctor recognizes revenue on a cash basis, because collection patterns across Medicare, Medicaid and private insurers are still too variable to satisfy the typical revenue recognition criteria at the time of service. That conservative stance means reported revenue significantly lags underlying visit volumes, but it also reflects the reality of navigating a complex reimbursement landscape. Management noted the current revenue numbers for the quarter represent only 3% of the projected U.S. revenue, which should make sense to any investor who has personally navigated the health care insurance billing and payment landscape in the country. It can take months for bills to actually be paid.
Ongoing Payer Growth
Underpinning that volume growth is the payer story. Over the past several months, Rocket Doctor has signed multiple in‑network agreements across California, New York and Maryland. Taken together, those contracts now give the company access to roughly 21 million insured lives, including Medicaid, Medicare and commercial plans. The still-expanding footprint has been built, but monetization is in the early stages. If collections and utilization scale as hoped, that covered‑lives base could drive a very different revenue profile over the next few quarters.
So that is the task ahead for Rocket Doctor AI – grow the market share and patient acquisition from the pool of potential customers that now sits at 21 million people. The company is spending to reach those patients, and once they visit the chances are very high they will be back again as 45% of patients in Canada are returning patients. Retain patients, reach new ones, add doctors, keep the growth compounding…. The company has also re-iterated that it has initiated a multi-state expansion strategy to systematically further broaden its U.S. clinical footprint throughout 2026.
Margins remain a bright spot, even if they’re coming down from very high levels. Gross margin was 75% in the quarter, versus 84% in Q4 and 88% in Q3. Management attributes that compression to a shift in revenue mix as the digital health platform and marketplace scale, bringing more variable costs tied to higher visit volumes. For an investor, the key takeaway is that this is still a software‑heavy, asset‑light model with room to generate attractive unit economics, but it’s also moving from “early, low‑volume, very high margin” into more normal operating territory as the network grows.
The Takeaway
Stepping back, the story that emerges from this quarter is fairly straightforward. Rocket Doctor AI has: modest but growing revenue, strong gross margins, and a rapidly expanding U.S. footprint anchored by in‑network payer contracts. The company is clearly spending to build out its technology stack, provider network and payer relationships, betting that access to 21 million covered lives and a physician‑led, AI‑enabled platform can translate into a much larger business over time.
For investors, the key questions are less about whether the model can grow from here and more about the pace and efficiency of that growth. Can visit volumes and B2B deals scale quickly enough to outpace operating expense growth? Will payer mix and collections support the kind of margin profile implied by a 70‑plus percent gross margin business? Those are the levers that will determine whether today’s early‑stage losses evolve into a sustainable, high‑margin digital health platform or remain an interesting but niche virtual care story.
Interested investors are encouraged to tune into Rocket Doctor AI’s Town Hall, with management discussing the growth to this point and the plan to expand further in 2026 and beyond.
Event Details
- What: Rocket Doctor AI Inc. Company Town Hall
- When: Wednesday, June 3, 2026
- Time: 11:00 AM Pacific Standard Time/2:00 PM Eastern Standard Time
- Link: Zoom Webinar: https://zoom.us/j/96953488892
Sponsored Content Disclosure: This article is sponsored by Rocket Doctor AI. SECFilings.com has partnered with the company to help share its story with a broader audience of investors and industry followers. SECFilings.com is being compensated $15,000 USD per quarter by 45 Degrees Inc. While we strive to present accurate information and maintain editorial standards, this content is part of a paid awareness initiative. Please do your own research and consult a licensed advisor before making investment decisions.
